Background and Purpose-Whether angiotensin-converting enzyme (ACE) inhibitors have any clinically significant antiatherogenic effects in humans remains unproven. We undertook a prospective randomized clinical trial of 98 patients with non-insulin-dependent diabetes mellitus (NIDDM) to examine the efficacy of ACE inhibition with enalapril for preventing intima-media (IM) thickening of the carotid wall as measured ultrasonographically. Methods-Ninety-eight NIDDM patients were randomly assigned either to enalapril at 10 mg/d (nϭ48) or to a control group (nϭ50); the planned duration of the trial was 2 years. All patients were seen at baseline (study entry) and 2 subsequent formal annual evaluations, in addition to standard clinical management for NIDDM. IM thickening and vascular lumen diameters were determined for all patients on the basis of baseline and 2 subsequent annual evaluations with carotid ultrasonography. We performed an intent-to-treat analysis to assess changes in IM thickening over the course of the study. 
D
iabetes mellitus (DM) is an important risk factor for coronary artery disease, arteriosclerosis obliterans, and stroke. 1 An increase in intima-media thickness (IMT) has been demonstrated in DM patients. 2 ,3 DM and mean fasting glucose level have been found to be positively associated with increased IMT of the common carotid artery but not IMT of the internal carotid artery, and hypercholesterolemia has been found to be related to plaque in the internal carotid artery. 4, 5 Angiotensin-converting enzyme (ACE) inhibitors and angiotensin II (Ang II) receptor antagonists have been used to prevent vascular smooth muscle cell (SMC) migration and growth, neointima formation, and accumulation of cholesterol in the aorta in experimental models. 6 -8 Bonithon-Kopp et al 9 showed that long-term exposure to high levels of plasma ACE resulted in structural alterations in the arterial wall.
It is well known that ACE inhibitor has a therapeutic effect on DM nephropathy. However, Hosoi et al 10 have reported that ACE may be a risk factor for the development of wall thickening of the carotid artery in patients with non-insulindependent diabetes mellitus (NIDDM), although the mechanism of increasing arterial wall thickness in DM has not been elucidated. Moreover, ACE inhibitor therapy has not been shown to reduce restenosis after balloon catheter-induced arterial injury in the clinical setting. 11 Previous studies 12, 13 have investigated ACE inhibitor efficacy relative to the common carotid artery IMT, but with equivocal results. More recently, the Heart Outcomes Prevention Evaluation (HOPE) Study 14 showed that treatment with ramipril, an ACE inhibitor, reduced the rates of death, myocardial infarction, stroke, coronary revascularization, cardiac arrest, and heart failure as well as the risk of complications related to diabetes and of diabetes itself. Whether ACE inhibition has any clinically significant antiatherogenic effect in humans remains unproven.
We undertook a prospective randomized longitudinal study of 98 NIDDM patients, the purpose of which was to examine the efficacy of ACE inhibition with enalapril for preventing intima-media (IM) thickening of the carotid wall as measured ultrasonographically.
Subjects and Methods

Subjects and Study Protocol
At the outset of the study, 170 NIDDM patients, as established by World Health Organization criteria, were being seen at Kagawa Medical University and Takamatsu National Hospital (K.M., M.K., Y.H., H.M.). It was our intention to offer study entry to all of these patients. Exclusion criteria constituted prior or concurrent history of ACE inhibitor (nϭ14), prior or concurrent antiplatelet therapy (nϭ17), prior or concurrent anticoagulant therapy (nϭ11) (with nϭ7 patients reporting both antiplatelet and anticoagulant therapy), other history of ischemic events (nϭ16), or refusal to grant informed consent (nϭ21). The 98 remaining patients were randomly assigned either to the enalapril treatment group (nϭ48), with treatment consisting of enalapril at 10 mg/d, or the control group (nϭ50), who did not receive enalapril. Patients were classified as hypertensive if they had systolic blood pressure Ͼ160 mm Hg, diastolic blood pressure Ͼ95 mm Hg, and/or were taking antihypertensive medication. Patients were classified as hyperlipidemic if they had total cholesterol Ͼ220 mg/dL, LDL cholesterol Ͼ140 mg/dL, triglyceride Ͼ150 mg/dL, and/or were taking antihyperlipidemic medication. We used a simple randomization scheme with treatment assignment initially determined by computerized random number generation in a sequential manner and then provided to the clinical investigators in sealed envelopes. Demographic and clinical data were available on all patients. In this regard, patients were categorized as either nonsmokers (never smoked or quit Ͼ10 years previously) or smokers (current and recent past smokers) at baseline. All patients had been receiving Ն1 of the following: sulfonylurea and/or acarbose for NIDDM, a Ca 2ϩ channel blocker and/or ␣-blocker for hypertension, and a 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor and/or clofibrate derivative for hyperlipidemia. Baseline measurements were taken at time of study entry; formal follow-up measurements were scheduled at 1 year and a minimum of 2 years after study entry. Protocol compliance was assessed for each patient, both at the planned annual evaluation periods and at each routine outpatient visit. Enalapril-treated patients who stopped taking enalapril because of coughing side effects or other reasons, control patients who started taking an ACE inhibitor during the duration of the trial, or any patients who had an ischemic event or started taking an antiplatelet or anticoagulant drug during the duration of the trial were considered protocol violators. Numbers of protocol violators were small: nϭ4 (8.3%) in the treatment group and nϭ3 (6%) in the control group. A trial profile is given in the Figure. 15 The trial protocol followed the principles outlined in the Declaration of Helsinki.
Carotid Ultrasonography Measurements
At baseline and at the 2 subsequent annual evaluations, carotid 2-dimensional echo imaging was performed in all patients with a 7.5-MHz transducer with an axial resolution of Ͻ0.20 mm (SSD-650, Aloka [at Kagawa Medical University] or SSH-160A, Toshiba [at Takamatsu National Hospital]). All recordings were performed by a trained sonographer (N.H.) who was blinded to the patient profiles and treatment assignment. With the patient seated, 2-dimensional longitudinal images of the bilateral extracranial carotid arteries were photographed (resolutionϭ0.093 mm) at end-diastole, defined as the top of the R wave on a simultaneous ECG. All measurements were done in the morning.
Each photograph was loaded into a computer system (Macintosh Quadra 650) with a graphic scanner at 1200 pixels per inch. The National Institutes of Health Image program was used to analyze the morphology of right and left common carotid arteries. We selected a morphological landmark on the baseline image, and the follow-up images (at 12 months and at a minimum of 24 months from the study entry) were made at the same site. Measurements consisted of IMT, defined as the distance between the intimal and adventitial leading edges, and vascular lumen diameter, defined as the distance between the lumen-intimal edges of the near and far walls. 16 Measurements were performed within the area from 20 to 30 mm proximal to the tip of the flow divider of the carotid bifurcation. For IMT we measured at 6 sites, including 3 on both the near and far walls, and for vascular lumen diameter we measured at those same sites in each artery. The respective average values were used for analysis. Atherosclerotic lesions of Ͼ1.0 mm in IMT were defined as plaques 17 and were excluded from measurement. We calculated annual IM thickening (mm/y) of common carotid arteries as (End Point IMTϪBaseline IMT)/Observation Interval, and we calculated annual change in vascular lumen diameter (mm/y) of common carotid arteries as (End Point Vascular Lumen DiameterϪBaseline Vascular Diameter)/ Observation Interval. Relative changes were calculated by normalizing by baseline values.
All readings of the images were performed by 1 physician (H.O.) who was blinded to patient treatment assignment, as well as the time sequence of images within each patient (baseline, year 1, or end point).
To estimate the reproducibility of IMT and vascular lumen diameter recordings (all by N.H.), carotid artery images were recorded 10 times within 1 day in a healthy volunteer. Intraday reproducibility was estimated from the coefficients of variation of the evaluations. Similarly, carotid artery images were also recorded Trial profile.
once a day for 10 days in another healthy volunteer; interday reproducibility was then estimated from the coefficients of variation of these evaluations.
Blood Pressure Measurements
Blood pressure was measured at baseline and the 2 subsequent annual examinations with a mercury sphygmomanometer in a standardized fashion, after 10 minutes of rest with the subject in the supine position. Systolic and diastolic blood pressures (mm Hg) were defined according to Korotkoff sounds I and V. All blood pressure measurements were done just before carotid ultrasound measurements and were performed by a physician who was blinded as to the patients' profiles and treatment assignments.
Serum Glucose, Plasma Lipoprotein, and Glycosylated Hemoglobin
Serum glucose (mg/dL), total cholesterol (mg/dL), triglyceride (mg/dL), HDL cholesterol (mg/dL), and glycosylated hemoglobin (HbA 1c ) (%) were measured at baseline and the subsequent annual follow-up clinical examinations. LDL cholesterol (mg/dL) was calculated as Total CholesterolϪ(HDL CholesterolϪTriglyceride/5.0).
Body Mass Index
All subjects were weighed without clothing, other than underwear, with the use of the same scale. Height was measured with a special ruler affixed to the wall. Body mass index was subsequently calculated as Weight in Kilograms/(Height in Meters) 2 .
Statistical Considerations
Our primary end point was change in IMT over the course of the study. This is an intent-to-treat analysis, under which we consider IMT values for all patients initially randomized to the enalapril group or the control group, regardless of subsequent protocol violation. Our sample size of 98 NIDDM patients (48 enalapril, 50 control) is sufficient to detect a moderate effect size (that is, difference in means of the 2 groups, divided by the common SD) of 0.5 with a statistical power of 0.7 or a large effect size of 0.85 with a power Ͼ0.9 when treatment groups are compared, with a 2-sided t statistic at conventional ␣ level 0.05. Summary statistics are presented as meanϮSD. Differences between the 2 groups at each observation period were assessed with ANOVA; within-and between-group comparisons across the baseline and follow-up recordings were made with repeated-measures ANOVA. Best subsets linear regression 18 was used to determine the effect of ACE treatment along with other potential covariates or predictors (demographics, baseline clinical data) on annual IM thickening and annual change in vascular lumen diameters. In this regard, we performed separate regression analyses for left and right carotid arteries but found few differences of note; hence, we report here regression analyses performed on the IMT and diameter data averaged within each patient.
Results
Clinical Characteristics
Four patients in the enalapril group and 3 patients in the control group were protocol violators. We here report an intent-to-treat analysis, whereby we evaluate all 48 patients initially randomized to the enalapril group and the 50 patients initially randomized to the control group. With regard to baseline characteristics, the enalapril-treated and control groups were well balanced with regard to age, sex, body mass index, prevalence of smoking, proteinuria, hypertension, hyperlipidemia, family history of an ischemic event (coronary artery disease, arteriosclerosis obliterans, or stroke), or medications received (Ca 2ϩ channel blocker, insulin, sulfonylurea, acarbose). No patient took metformin medication. Summary values are given in Table 1 .
Atherosclerotic Parameters
Using repeated-measures ANOVA with 1 grouping factor (treatment group), we found no statistically significant differences between the enalapril-treated and control groups in any of the atherosclerotic parameters (systolic or diastolic blood pressures, serum glucose, HbA 1c , total cholesterol, triglyceride, HDL cholesterol, or LDL cholesterol) over the baseline and follow-up measurements. Using 1-way repeatedmeasures ANOVA within each treatment group, we found 3 nominally significant time trends in atherosclerotic parameters: (1) a linear trend in serum glucose levels in the control group (F 1,49 ϭ5.14, Pϭ0.028); (2) a quadratic trend in HDL cholesterol in the control group (F 1,49 ϭ4.24, Pϭ0.045); and (3) a decrease in systolic blood pressure in the enalapriltreated group at years 1 and 2 relative to baseline (F 1,47 ϭ13.95, PϽ0.0005). Summary statistics are given in Table 2 .
Carotid Ultrasonography Measurements
All carotid ultrasonography measurements were made solely by 1 investigator (N.H.) to eliminate interobserver variability. Intraday and interday reproducibility values of the investigator were quite acceptable: the intraday coefficients of variation of IMT and vascular lumen diameter of common carotid arteries were 2.7% and 2.1%, respectively, and the interday coefficients of variation of IMT and vascular lumen diameter were 6.1% and 5.1%, respectively. Ninety-eight common carotid arteries, for both the right and left arteries of each patient, were evaluated in this study (the enalapril-treated group comprised 48 patients, and the control group comprised 50 patients) ( Table 3) . Annual IM thickening measurements of the right and left common carotid arteries were 0.01Ϯ0.02 and 0.01Ϯ0.02 mm/y in the enalapril-treated group and 0.02Ϯ0.03 and 0.02Ϯ0.02 mm/y in the control group, respectively. From regression analysis, annual IM thickening was found to be predicted by enalapril 
Discussion
An increase of IMT of the common carotid artery is related to increased prevalence of myocardial infarction, angina, cerebrovascular disease, and peripheral vascular disease 19, 20 and is also associated with an increased risk of stroke and myocardial infarction. 21, 22 Previous studies have suggested that DM 2,23 and insulin 24 are related to increased stiffness of the arterial wall in humans. DM and mean fasting glucose level have been found to be positively associated with increased IMT of the common carotid artery but not IMT of the internal carotid artery. This pattern is different from hypercholesterolemia, which is related to plaque in the internal carotid arteries. 4 DM is one of the most important risk factors for coronary artery disease, arteriosclerosis obliterans, and stroke. 1 Many studies are focused on the prevention of coronary artery disease, arteriosclerosis obliterans, and stroke modulating IM thickening and plaques. 12,13, 25 Touboul et al 26 reported that the risk of brain infarction increased continuously with increasing IMT of the common carotid artery. Recently, the HOPE Study 14 showed that treatment with ramipril, an ACE inhibitor, reduced the rates of death, myocardial infarction, stroke, coronary revascularization, cardiac arrest, and heart failure as well as the risk of complications related to diabetes and of diabetes itself. Few other interventional studies had been undertaken aimed at the prevention of the atherosclerosis process in DM patients. In the present study we focused on NIDDM patients in the setting of a randomized clinical trial and found that, over time, IM thickening in these patients could be predicted by enalapril use, sex, and insulin use. Ang II receptors, ACE, 27 and angiotensinogen messenger RNA 28 have been identified as humoral factors in the vascular wall in rats, and several lines of evidence have supported the role of a local renin-angiotensin system in the pathogenesis of neointima formation induced by vascular injury in rats. 6 ACE inhibitors and Ang II receptor antagonists have been reported to prevent vascular SMC migration and growth, neointima formation, and accumulation of cholesterol in balloon injury models of rats and rabbits. 6 -8 In 1 study long-term treatment with ACE inhibitors reduced myointimal thickening induced by balloon injury in rat carotid artery or aorta. 6 Hosoi et al 10 showed that ACE insertion/deletion polymorphism is a ge- netic factor that may predict the progression of carotid atherosclerosis in NIDDM patients. Our results support the findings of these previous studies and suggest that long-term treatment with an ACE inhibitor (enalapril) slows progressive IM thickening of the common carotid artery in NIDDM patients. Ultrasound methods that quantify the size of atherosclerotic lesions and arterial wall thickness are now commonly used in longitudinal studies of the time course of atherosclerosis. These measurements are dependent on high-resolution B-mode ultrasonography, a method that presents the arterial wall as a double-line pattern. Previous studies 29, 30 have reported a significant correlation between atherosclerotic changes and IMT. Persson et al 30 showed that IMT values measured ultrasonographically and microscopically were closely correlated (rϭ0.82, PϽ0.001), with IMT determined by light microscopy consistently smaller than that determined by ultrasonography (mean difference, 0.14 mm). They attributed the difference between ultrasound-and light microscopy-determined IMT to shrinkage of soft tissues during histological preparations. We have relied solely on ultrasound measurements for outcome analyses in the present study; in this regard, we note that any systematic bias in ultrasound measurements would be of little consequence because our primary end point relates to changes in vessel sizes over time rather than absolute magnitudes.
IMT and vascular lumen diameter of the same macrovascular artery will vary together under conditions of high and low blood pressure. Under high blood pressure, macrovasculatures are distended and have a strong wall tension, making IMT thin and IM thickening faster. Conversely, under low blood pressure, macrovasculatures are constricted and have a low wall tension, making IMT wide and IM thickening slower. Enalapril, the ACE inhibitor used in the present trial, acts as a vasodilator of microvessels, reduces blood pressure, and decreases hemorheologic stress and vascular wall tension. Previous studies 12, 13 that have investigated ACE inhibitor efficacy for IMT of common carotid arteries in hypertensive patients could not definitively establish therapeutic efficacy. However, the observation periods of these studies ranged from 6 to 9 months, in contrast to the planned 24-month observation period in our trial. These previous studies reported mean reductions in blood pressure between baseline and follow-up measurements. In our trial systolic blood pressures decreased on average by 4.8 mm Hg during the first year and were maintained at the same level during the second year in the enalapril-treated group. This decreased systolic blood pressure during the first period may slightly constrict the common carotid artery during the same period and may transiently increase the apparent IMT, which may in turn decrease the wall tension and eventually slow the rate of IM thickening. From these various findings, we conclude that a minimum 2-year observation period should be incorporated into any future trials that evaluate therapeutic regimens on IMT to preclude possible early (up to 1 year) confounding of transient or apparent effects due to decreased systolic blood pressures. The Study to Evaluate Carotid Ultrasound Changes in Patients Treated With Ramipril and Vitamin E (SECURE) trial, a substudy of the HOPE Study, has examined the effect of ramipril on IM thickening with 4 years of follow-up in 732 patients with cardiovascular disease or with diabetes and additional risk factors. 25 In their study annual IM thickening was 0.0217 mm/y in the placebo group and 0.0137 mm/y in the ramipril (10 mg/d) group (Pϭ0.033).
The Asymptomatic Carotid Artery Progression Study research group has estimated annual IM thickening of common carotid arteries as 0.006 mm/y in patients with coronary risk factors. 31 In comparison, Handa et al 29 .001, by repeated-measures ANOVA to assess differences in IMT and vascular lumen diameter between control and enarapril-treated groups and by ANOVA to assess differences in annual changes between control and enarapril-treated groups.
NIDDM patients. The faster annual IM thickening of carotid arteries in the aforementioned studies may reflect the characteristic differences in the study population compared with the present study. Patients in the aforementioned studies had higher HbA 1c and older age than those in the present study. Nevertheless, in the present study annual IM thickening values of the right and left common carotid arteries were reduced to 0.01Ϯ0.02 and 0.01Ϯ0.02 mm/y in the enalapriltreated group, respectively. Thus, long-term treatment with enalapril can slow progressive IM thickening of common carotid arteries.
The magnitude of change in vascular lumen diameters of common carotid arteries over the course of our study was modest. This may be attributable to our exclusion of atherosclerotic lesions of Ͼ1.0 mm in IMT from consideration. Glagov et al 33 showed that, before stenosis is Ͼ40%, the actual lumen area seems to remain independent of the plaque area, reflecting the corresponding increase in arterial size. In our study we measured IMT and vascular lumen diameter in common carotid arteries that showed no plaque (0% stenosis). This should yield precise estimation of early changes of IMT in NIDDM.
Potential limitations of this study might include the limited sample size and lack of placebo control. Our sample size of 98 is modest in comparison to enrollments in large multicenter trials; however, our sample size calculation (mentioned previously) does establish that the trial was sufficiently powered to find moderate effect sizes, if they indeed existed. We recognize that our control group was not given a placebo. However, given the duration of our study (minimum of 2 years), whatever placebo effect might be anticipated at the outset of the trial would surely be dissipated by the end. Additionally, our end point-IM thickening-is clearly objective and would reasonably be totally insensitive to any placebo effect. Furthermore, patients were randomly assigned to treatment arms, and our evaluators remained blinded to treatment assignment; therefore, we would argue that no bias was introduced by the failure to dispense a placebo.
In summary, we used enalapril to evaluate the effect of an ACE inhibitor. From our findings, we conclude that enalapril is effective in slowing progressive IM thickening in NIDDM patients. This slowing effect of enalapril may be the mechanism whereby an ACE inhibitor reduced the incidence of cardiovascular events (cardiovascular death, myocardial infarction, and stroke) in the HOPE Study. 14 We believe that this is likely to be a class effect, since previous studies have shown that many other ACE inhibitors (cilazapril, perindopril, captopril, and fosinopril) also prevent neointima formation and inhibit the development of atherosclerosis in hypercholesterolemia 6 -8 ; ramipril also slows progressive IM thickening of the carotid arteries in patients with cardiovascular disease or with diabetes and additional risk factors. 25 However, in the Quinapril Ischemic Event Trial (QUIET), quinapril did not reduce progression of coronary atherosclerosis, a new stenosis development, in patients with coronary artery disease in the absence of congestive heart failure and/or hyperlipidemia (the prevalence of hypertension was 47%, and that of diabetes [type 2] was 16%). 34 Previous studies have also shown that an angiotensin subtype 1 receptor antagonist markedly suppressed myointimal thickening and reduced neointima formation in an experimental model. 7, 35 However, the effect of Ang II receptor antagonists remains controversial; further studies will be necessary to establish whether Ang II receptor antagonists have any clinically significant antiatherogenic effect in humans.
